TransMedics Group (TMDX) Competitors $65.70 +1.48 (+2.30%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TMDX vs. GKOS, BLCO, INSP, PRCT, AXNX, NVCR, NVST, NARI, IRTC, and LIVNShould you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Axonics (AXNX), NovoCure (NVCR), Envista (NVST), Inari Medical (NARI), iRhythm Technologies (IRTC), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. TransMedics Group vs. Glaukos Bausch + Lomb Inspire Medical Systems PROCEPT BioRobotics Axonics NovoCure Envista Inari Medical iRhythm Technologies LivaNova Glaukos (NYSE:GKOS) and TransMedics Group (NASDAQ:TMDX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk. Does the MarketBeat Community prefer GKOS or TMDX? Glaukos received 333 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 64.72% of users gave Glaukos an outperform vote while only 59.36% of users gave TransMedics Group an outperform vote. CompanyUnderperformOutperformGlaukosOutperform Votes44464.72% Underperform Votes24235.28% TransMedics GroupOutperform Votes11159.36% Underperform Votes7640.64% Is GKOS or TMDX more profitable? TransMedics Group has a net margin of 8.14% compared to Glaukos' net margin of -42.43%. TransMedics Group's return on equity of 18.74% beat Glaukos' return on equity.Company Net Margins Return on Equity Return on Assets Glaukos-42.43% -18.99% -11.47% TransMedics Group 8.14%18.74%4.39% Which has stronger earnings & valuation, GKOS or TMDX? TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlaukos$360.35M22.39-$134.66M-$3.02-48.46TransMedics Group$401.09M5.50-$25.03M$0.9469.90 Which has more risk and volatility, GKOS or TMDX? Glaukos has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Do analysts prefer GKOS or TMDX? Glaukos presently has a consensus price target of $143.17, suggesting a potential downside of 2.18%. TransMedics Group has a consensus price target of $122.70, suggesting a potential upside of 86.74%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than Glaukos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Glaukos 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.85TransMedics Group 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82 Does the media refer more to GKOS or TMDX? In the previous week, TransMedics Group had 13 more articles in the media than Glaukos. MarketBeat recorded 31 mentions for TransMedics Group and 18 mentions for Glaukos. Glaukos' average media sentiment score of 0.87 beat TransMedics Group's score of 0.28 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 9 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 6 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in GKOS or TMDX? 99.0% of Glaukos shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 6.4% of Glaukos shares are held by company insiders. Comparatively, 7.0% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryTransMedics Group beats Glaukos on 12 of the 18 factors compared between the two stocks. Ad Banyan Hill PublishingTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.Click here and I’ll show you exactly how to position your money Get TransMedics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TMDX vs. The Competition Export to ExcelMetricTransMedics GroupElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.16B$3.10B$5.14B$9.31BDividend YieldN/A1.73%4.81%4.06%P/E Ratio69.9018.44135.1917.53Price / Sales5.5054.581,232.15140.37Price / Cash451.4539.9140.6537.95Price / Book15.643.754.884.92Net Income-$25.03M$90.26M$118.97M$225.78M7 Day Performance-2.46%-3.87%15.41%-1.58%1 Month Performance-18.81%2.12%15.47%6.67%1 Year Performance-14.52%8.57%34.58%22.48% TransMedics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TMDXTransMedics Group4.0954 of 5 stars$65.71+2.3%$122.70+86.7%-15.2%$2.16B$401.09M69.90210Analyst ForecastGap DownGKOSGlaukos4.1648 of 5 stars$143.87+3.6%$143.17-0.5%+79.6%$7.93B$360.35M-46.00780Short Interest ↓BLCOBausch + Lomb2.2694 of 5 stars$18.64+0.2%$20.58+10.4%+24.3%$6.56B$4.68B-17.7113,300Short Interest ↑INSPInspire Medical Systems4.7463 of 5 stars$188.35+0.3%$233.58+24.0%+1.4%$5.64B$755.59M176.781,011Short Interest ↓Positive NewsPRCTPROCEPT BioRobotics2.917 of 5 stars$89.54+0.3%$97.86+9.3%+104.0%$4.67B$136.19M0.00626Positive NewsAXNXAxonics1.1748 of 5 stars$70.98+0.8%$71.00+0.0%+21.8%$3.63B$366.38M-591.45610High Trading VolumeNVCRNovoCure2.7127 of 5 stars$32.84-1.7%$32.67-0.5%+136.7%$3.55B$577.74M-23.861,453NVSTEnvista3.6292 of 5 stars$19.58+0.6%$20.65+5.5%-19.3%$3.37B$2.50B-2.5112,800Positive NewsNARIInari Medical2.56 of 5 stars$55.39-0.4%$58.89+6.3%-13.5%$3.24B$574.50M-41.181,300Analyst ForecastIRTCiRhythm Technologies3.0458 of 5 stars$89.42+3.5%$107.82+20.6%-9.5%$2.80B$492.68M-17.782,000LIVNLivaNova3.9591 of 5 stars$50.01-2.9%$69.17+38.3%-0.3%$2.72B$1.24B122.622,900Analyst UpgradePositive News Related Companies and Tools Related Companies Glaukos Alternatives Bausch + Lomb Alternatives Inspire Medical Systems Alternatives PROCEPT BioRobotics Alternatives Axonics Alternatives NovoCure Alternatives Envista Alternatives Inari Medical Alternatives iRhythm Technologies Alternatives LivaNova Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TMDX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TMDX Stock Alerts